Asosiy kontentga oʻtish
Sharh maqola

Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification

Sara De BrouwerKarolinska InstitutetKatleen De PreterAmsterdam UMC Location University of AmsterdamCandy KumpsEmma KinderziekenhuisPiotr ZabrockiAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, SwedMichaël PorcuAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden; 14Division of BiochEllen M. WesterhoutKU LeuvenArjan LakemanKU LeuvenJo VandesompeleEmma KinderziekenhuisJasmien HoebeeckUniversity of AmsterdamTom Van MaerkenKU LeuvenAnne De PaepeUniversity of AmsterdamGeneviève LaureysKarolinska InstitutetJohannes H. SchulteEmma KinderziekenhuisAlexander SchrammUniversity of AmsterdamCaroline Van den BroeckeAmsterdam UMC Location University of AmsterdamJoëlle VermeulenAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden; 14Division of BiochNadine Van RoyAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden; 14Division of BiochKlaus BeiskeEmma KinderziekenhuisMarleen RenardKarolinska InstitutetRosa NogueraAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden; 14Division of BiochOlivier DelattreKU LeuvenIsabelle Janoueix‐LeroseyKarolinska InstitutetPer KognerAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden; 14Division of BiochTommy MartinssonKarolinska InstitutetAkira NakagawaraUniversity of AmsterdamMiki OhiraAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden; 14Division of BiochHuib N. CaronAuthors' Affiliations: 1Center for Medical Genetics, 2Department of Paediatric Haematology and Oncology, and 3Department of Pathology, Ghent University Hospital, Ghent, Belgium; 4Department of Molecular and Developmental Genetics, K.U.Leuven-VIB, and 5Department of Paediatrics, University Hospital Leuven, Leuven, Belgium; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, and 7Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands; 8Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; 9Department of Pathology, Rikshospitalet, Oslo, Norway; 10Department of Pathology, Medical School of Valencia, University of Valencia, Valencia, Spain; 11INSERM U830, Institut Curie, Paris, France; 12Childhood Cancer Research Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden; 13Department of Clinical Genetics, Gothenburg University, Gothenburg, SwedAngelika EggertKarolinska InstitutetJan CoolsKarolinska InstitutetRogier VersteegKU LeuvenFrank SpelemanKarolinska Institutet
2010en
ABI

Annotatsiya

PURPOSE: Activating mutations of the anaplastic lymphoma kinase (ALK) were recently described in neuroblastoma. We carried out a meta-analysis of 709 neuroblastoma tumors to determine their frequency and mutation spectrum in relation to genomic and clinical parameters, and studied the prognostic significance of ALK copy number and expression. EXPERIMENTAL DESIGN: The frequency and type of ALK mutations, copy number gain, and expression were analyzed in a new series of 254 neuroblastoma tumors. Data from 455 published cases were used for further in-depth analysis. RESULTS: ALK mutations were present in 6.9% of 709 investigated tumors, and mutations were found in similar frequencies in favorable [International Neuroblastoma Staging System (INSS) 1, 2, and 4S; 5.7%] and unfavorable (INSS 3 and 4; 7.5%) neuroblastomas (P = 0.087). Two hotspot mutations, at positions R1275 and F1174, were observed (49% and 34.7% of the mutated cases, respectively). Interestingly, the F1174 mutations occurred in a high proportion of MYCN-amplified cases (P = 0.001), and this combined occurrence was associated with a particular poor outcome, suggesting a positive cooperative effect between both aberrations. Furthermore, the F1174L mutant was characterized by a higher degree of autophosphorylation and a more potent transforming capacity as compared with the R1275Q mutant. Chromosome 2p gains, including the ALK locus (91.8%), were associated with a significantly increased ALK expression, which was also correlated with poor survival. CONCLUSIONS: ALK mutations occur in equal frequencies across all genomic subtypes, but F1174L mutants are observed in a higher frequency of MYCN-amplified tumors and show increased transforming capacity as compared with the R1275Q mutants.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba